German drugmaker Boehringer Ingelheim and Denmark’s Zealand Pharma have reported positive Phase 3 results for their experimental obesity drug survodutide, which met its primary cardiovascular safety endpoint in a trial involving 5,530 patients and delivered estimated weight loss of up to 13.7% at 72 weeks. However, about one in five patients receiving the drug stopped treatment because of gastrointestinal side effects.
IQVIA